

Govt. of India
Ministry of Health & Family Welfare
Dte. General of Health Services,
(Medical Stores Organisation)
Government Medical Store Depot,
Kolkata – 700022.

Minutes of the Pre-bid Meeting

Tender No. 13(F-34)/PS/Tender/2025-26
Tender ID: 2026_DGHS_904967_1

Subject: Rate Contract for 101 Group-B Generic Drugs

The Pre-bid Meeting in respect of above Tender is held on 13.04.2026 at 11.00 Hours in the Conference Room of GMSD, Kolkata under the Chairpersonship of Dr. Anju Nanda, DDG(Stores), MSO, New Delhi.

The meeting was attended by officers/ officials of MSO/GMSD and representatives of prospective bidders. The following departmental officers were present during the meeting.

1. Dr. Bidyut Paul, Sr. CMO (SAG), In-Charge, GMSD, Kolkata.
2. Dr. Shampa Maitra, Sr. CMO(SAG), CGHS, Kolkata
3. Sh. Soumitra Pramanick, Sr. Accounts Officer, GMSD, Kolkata.
4. Sh. Basanta Kumar Hens, Asstt. Depot Manager, GMSD, Kolkata
5. Sh. Tushar Kanti Hira, Depot Supdt. GMSD, Kolkata
6. Sh. Rajesh Kumar Sadhukhan, Depot Supdt., GMSD, Kolkata
7. Sh. Hemant Kumar Rai, PCC, GMSD, Kolkata
8. Sh. Tamoghna Acharya, UDC, GMSD, Kolkata

At the outset, the Chairperson welcomed all participants and informed that all queries received through email and letters, as well as those raised during the meeting, would be duly examined. It was further informed that the clarifications issued during the Pre-bid meeting shall form an integral part of the tender document.

All queries received were examined and consolidated under thematic areas. The decisions taken are in accordance with tender conditions, GFR 2017, and principles of transparency, fairness and competition.

Clarifications & Decisions:

All queries were examined and consolidated under thematic areas. No modification in eligibility criteria, warehouse requirements, delivery period, regulatory compliance and technical specification was considered, necessary unless explicitly clarified certain operational relaxations and documentation clarifications have been allowed as detailed in the MOM.

A summary of bidder-wise queries and their disposition is placed at Annexure-1. Detailed clarifications have been issued in thematic form to ensure uniformity and transparency.

With regard to **eligibility criteria including turnover requirements, mandatory warehouse conditions under Annexure-K and requests for supply through distributors or CNF agents**, it was decided that no modification is warranted. The existing provisions have been framed to ensure reliable supply across all GMSDs, compliance with prescribed storage and distributor norms and timely execution of supply orders. Accordingly, **the requirements for maintaining warehouses in each GMSD jurisdictions shall remain unchanged unless specified further and requests for centralized or zonal warehousing models arrangements are not admissible.**

On the issue of **delivery period**, several bidders requested extension from 45 days to 60 days citing API shortages and logistical challenges. After due consideration, **the requests was not accepted.** The delivery period has stipulated in the tender is retained since it is aligned with operational requirements of GMSD/CGHS and is critical to ensuring uninterrupted availability of medicines.

Regarding **regulatory compliance**, particularly in respect of **fixed dose combination (FDCs)**, it was clarified that CDSO/ DCGI approval is mandatory wherever applicable. **Bidders shall submit valid CDSO/DCGI approval certificates for FDC drugs at the time of Bid submission, unless otherwise specified. No relaxation in regulatory requirements is permissible.**

With respect to **technical specifications**, including composition, strength, nomenclature and pharmacopoeial standards, requests for modifications were examined but not accepted. It is reiterated that the specifications provided in the **schedule of requirements (SOR)**, are to be strictly adhered to, and no deviation in composition or strength is permitted until specified further.

In relation to **dosage forms**, it is clarified that **Capsules and Tablet forms, Injection and Vials shall be treated at par**, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. **Value-added formulations** such as SR/CR/ER/XR/PR/MR etc are acceptable and will be treated at par for evaluation purpose.

On the matter of **packing and pack size**, it is clarified that **larger pack size may be accepted** subject to rate equivalence with the pack size specified in the SOR. **Alternative pack sizes**, such as strip of 15 tablets or capsules, may be considered provided all other tender conditions are complied with. **Rates shall be normalized appropriately on a per unit basis wherever required.**

Requests for **relaxation in shelf life** conditions, including acceptance of product with **lower shelf life** such as 18 months, will be **accepted until approved/specified by Drug Controller**. The shelf life criteria prescribed in the Tender document shall remain unchanged and must be strictly complied with.

With regard to **documentation requirement**, it is clarified that Annual Turnover certificates, Balance Sheets and Profit & Loss statements bearing valid UDIN shall be **accepted even if the tender ID is not mentioned**. Bidders are required to **submit sample of primary packing except for injectables, prior to tender opening** as per tender conditions. Third Party manufacturing or marketing arrangements **shall not be admissible** where specifically restricted under the tender provisions.

A specific operational **relaxation was considered** in respect of supply to **Karnal GMSD** from **Zirakhpur and Mohali warehouse**. Considering geographical proximity (satellite city) and operational feasibility, such shall be permitted. However, this relaxation is strictly case-specific and shall not be construed as a general waiver of the warehouse requirements prescribed under the tender.

Further, with regard to warehouse requirements, it is clarified that **warehouses located within the National Capital Region (NCR) of Delhi shall be considered** as meeting the requirement for GMSD New Delhi. Additionally, warehouses situated in locations falling within the common operational jurisdiction or geographical proximity of **Delhi NCR and Karnal shall be considered** valid for servicing both GMSD New Delhi and GMSD Karnal, subject to operational feasibility.

It is further informed that necessary corrections in item descriptions, including those identified during the pre-bid stage, shall be issued through a corrigendum on the CPP Portal.

Additional clarifications include that **larger pack sizes** may be accepted subject to rate parity, and **unit-based pricing** shall be **applicable** wherever relevant. **Existing Rate Contract holders may continue to supply medicines till the validity of their contracts. The roadmap for procurement cycle has already been communicated** and is available on the DVDMS portal.

With regard to **registration of manufacturing units** with MSO, it is clarified that bidders may **submit provisional documents** such as proof of application, including forms or acknowledgements, **at the time of bid submission**. However, submission of the **final valid registration certificate** shall be mandatory by the stage of technical evaluation i.e. on or **before 27th May, 2026**, failing which the bid shall be treated as non-responsive and liable for rejection.

With respect to submission of **Non-Conviction Certificate**, it is clarified that the certificate should preferably be **general in nature and not organization specific of tender-specific**. In case the certificate is organization-specific or tender-specific, it shall be considered valid only if it pertains specifically to this tender. **Certificate issued for any other organization or bearing reference to any other tender shall not be considered acceptable**. In cases where the validity period of the certificate is not explicitly mentioned, the same shall be treated as valid for a period of six months from the date of issue.

Regarding API traceability and **Batch Manufacturing Record (BMR)**, it is clarified that relaxation in submission of BMR shall be **applicable only in respect of imported products and Biological products** where items are accepted based on In-house Test Report as per the provisions of the tender document.

A collection of handwritten signatures and initials in blue ink, located at the bottom left of the page. The signatures are stylized and appear to be of various individuals, possibly officials or bidders.

With reference to the **Bill of Quantities (BOQ)**, it is clarified that the **rate unit indicated as '1'** shall be construed as the **unit rate** for the respective items. Accordingly, bidders are required to **quote rates on a per unit basis**, such as per tablet, capsule, bottle, tube, respule, inhaler, recap, respicap, kit, ampoule, vial, sachet, pre-filled syringe (PFS), oral dispersible strip (ODS), flexipen, cartridge or any other applicable unit as per the item description.

With regard to submission of the **tender document**, it is clarified that in view of the large file size, **bidders may submit the complete tender document, duly signed and stamped, along with the Integrity Pact** as per the prescribed requirements. However, at the time of submission of bids, bidders shall **mandatorily submit the first two pages and the last two pages of the tender document, duly signed and stamped by authorized signatory**, as a token of acceptance and for reference purpose.

It is clarified that provisions regarding **Global Tender Enquiry (GTE)** exemption shall be governed strictly as per the applicable provisions of GFR 2017 and the Public Procurement (Make in India) policy, as amended from time to time. No separate deviation is envisaged under this tender.

Annexure-I

Summary of Bidder-wise Queries and their Disposition.

Name of the firm	Queries and request for clarification/ amendments raised in the Pre-Bid meeting by the prospective bidders to the committee	Clarification
1. M/s. Bajaj Health Care Ltd.	Request for Amendment/ Clarification 1. There is no assured quantum of business even upon successful award of tender, making mandatory establishment of multiple depots commercially unviable 2. Establishing warehouses at all GMSD locations would involve significant recurring expenditure, which is not economically justified for either the bidder or the procurement system, especially when distributor-based supply is already operational 3. Requested to adopt a similar approach by permitting directly supply from manufacturers, which would enhance operational efficiency, ensure better supply chain control, and facilitate smoother and more reliable delivery of goods 4. Regarding DCGI permission for all Fixed dose combinations (FDCs) and new drugs quoted, requested to consider list of FDC drug approved by DCGI which is already available on their official portal and in the public portal as ESIC is also accepting same. 5. Due to America-Iran war situation acute shortage of API and disrupted whole supply chain however we request to kindly increase delivery period 60 days instead of 45 days 6. There is concession given to MSME firms regarding price preference, but MSME companies have limitations regarding warehouses at all GMSDs.	It is clarified that:- it is part of our approved tender document and cannot be changed. It was clarified that CDSCO approval/certificate for FDC may be furnished by the bidder at the time of bid submission It is clarified that the delivery period of 45 days is as per the approved tender conditions and cannot be increased. It is part of our approved tender document and cannot be changed.
2. M/s. Quickmed Pharmaceuticals	Non-Conviction certificate regarding	It was clarified that Non-Conviction Certificate either have the tender ID of this tender or in general without specifying any tender ID
3. M/s. Theon Pharmaceuticals Ltd.	1. Tender condition requiring "The bidder must have at least one warehouse in the state of each GMSD" along with the requirement of submitting Annexure-K may kindly be reconsidered and removed.	It is clarified that:- it is part of our approved tender document and cannot be changed.
4. M/s. Maxmed Lifesciences Pvt. Ltd.	1. Clause regarding multi-state warehouse/ Drug	It is clarified that:- it is part of our

	License/ GST Registration: The tender introduces a requirement for companies to have a warehouse, drug license, and GST registrations. 2.Revision in Turnover Criteria Rs.50 Cr. To 100 Cr. For Gr. B.	approved tender document and cannot be changed. 2. It is clarified that:- it is part of our approved tender document and cannot be changed
5.M/s, Stadmed Pvt. Ltd., Kolkata	1.Request to increase delivery period 60 days instead of 45 days. 2. Revision in Turnover Criteria Rs.50 Cr. To 100 Cr. For Gr. B. 3. Tender condition requiring "The bidder must have at least one warehouse in the state of each GMSD" along with the requirement of submitting Annexure-K may kindly be reconsidered and removed. 4. Market Standard Certificate	It. Is Clarified that:- The delivery period of 45 days is as per the approved tender condition and cannot be increase. 2. It is clarified that:- it is part of our approved tender document and cannot be changed. 3. It is clarified that:- it is part of our approved tender document and cannot be changed. 4. CA verified, self certified copy attached of previous year.
6. ZIM Lab. Ltd.	1. Certain biological, antibiotics and multivitamins formulations naturally have a shorter shelf life (e.g. 18 months), may list of exempted items or allow for products with 18 months shelf life provided they meet the 5/6 th residual life at the time of delivery.	The bidder may apply in written for shelf life relaxation for some specific item.
7.M/s, Aluenta Pharma Ltd.	1. Registration of Firm within bidding period	1. Participating in tender with evidence that applying for registration which must completed within 27/05/2026 otherwise participation cancel.
8.M/s, Aluenta Pharma Ltd.	1. Acceptable Dose forms	1. It is clarified that Capsules and Tablet forms, Injection and Vials shall be treated at par, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. Value-added formulations such as SR/CR/ER/XR/PR/MR etc are acceptable and will be treated at par for evaluation purpose
9.M/s, Elis Lifescience Ltd.	1. Packing and pack size	1. Larger pack sizes may be accepted subject to rate parity, and unit-based pricing shall be applicable wherever relevant. Existing Rate Contract holders may continue to supply medicines till the validity of their contracts


With reference to the above, the following queries were raised by the prospective bidder/s in the Pre-bid meeting and clarification was given by the Committee.


Sl. No.	Query Raised	Clarification
1	The representative from M/s. Bajaj Healthcare Ltd. Raised the query with respect to	
a	Annexure K Warehouse regarding	It was clarified that it is part of our approved tender document and cannot be changed
b	DCGI permission for FDC	It was clarified that DCGI permission certificate to be submitted
c	Enhancement of Delivery period from 45 days to 60 days	It was clarified that the original delivery period can be extended with penalty up to 42 days, i.e. total delivery period with penalty is 87 days. Penalty rate reduced to 0.5% per week.
2	The representative from M/s. Quickmed Pharmaceuticals Raised the query with respect to	
a	Non-Conviction Certificate	It was clarified that Non-conviction certificate either have the tender ID of this tender or in general without specifying any tender ID. Non-Conviction certificate in general valid for 6


		months only.
3	The representative from M/s. Stadmed Pvt. Ltd., Kolkata Raised the query with respect to	
a	Enhancement of Delivery period from 45 days to 60 days	It was clarified that the original delivery period can be extended with penalty up to 42 days, i.e. total delivery period with penalty is 87 days. Penalty rate reduced to 0.5% per week.
b	Revision of Turnover	It is clarified that:- it is part of our approved tender document and cannot be changed.
C	Annexure K Warehouse regarding	It was clarified that it is part of our approved tender document and cannot be changed
d	Market Standing Certificate	It was clarified that the 3 rd Party certificate is not admissible
4	The representative from M/s. ZIM Lab. Ltd. Raised the query with respect to	
a	Shelf life of the drugs	The bidder may apply in written for shelf life relaxation for some specific item.
5	The representative from M/s. Aluenta Pharma Ltd. Raised the query with respect to	
a	Registration of Firm within bidding period	Document for application of Registration to be submitted in the time of bidding and registration to completed within technical evaluation.
6	The representative from M/s. Alventa Pharma Ltd.. Raised the query with respect to	
a	Acceptable Dose form	It is clarified that Capsules and Tablet forms, Injection and Vials shall be treated at par, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. Value-added formulations such as SR/CR/ER/XR/PR/MR etc are acceptable and will be treated at par for evaluation purpose
7	The representative from M/s. Elis Lifescience Ltd. Raised the query with respect to	
a	Packing and pack size	Larger pack sizes may be accepted subject to rate parity, and unit-based pricing shall be applicable wherever relevant. Existing Rate Contract holders may continue to supply medicines till the validity of their contracts


These minutes, including all clarifications issued herein, shall form an integral part of the tender document. No further queries shall be entertained after issuance of these minutes.


The meeting concluded with a vote of thanks to the Chair.



Tamoghna Acharya
UDC



Hemant Kumar Rai
PCC



Rajesh Kumar Sadhukhan
Depot Supdt.



Tushar Kanti Hira
Depot Supdt.


Basanta Kumar Hens
Asstt. Depot Manager


Soumitra Pramanick
Sr. A. O.











Dr. Bidyut Paul
Sr.CMO(SAG) & I/c


Dr. Shampa Maitra
Sr. CMO (SAG)


Dr. Anju Nandā
DDG(Stores),MSO, DGHS








ATTENDANCE SHEET

The following officers/officials members of The Pre-bid Committee attended the Pre-bid meeting held on 10.04.2026 at 11.00 Hours at Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata 700022 against Tender Number: 13(F-34)/PS/Tender/2025-26 (Tender ID No. 2026_DGHS_904967_1) for Supply of 101 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Officer with Designation	Signature /Mobile No.
1.	Dr. Anju Nanda DDG(St),MSO (DGHS) R K Puram, New Delhi (Chairperson of the Committee)	
2.	Representative AD(MSD), CGHS, Kolkata (Member) Name : Dr. Shampa Maitra Designation : Sr. CMO (SAG)	 13/4/2026
3.	Dr. Bidyut Paul Sr. CMO(SAG), In charge GMSD, Kolkata (Member)	 13/4/26
4.	Shri Soumitra Pramanick Sr. Accounts Officer, GMSD, Kolkata (Member)	 13.4.26
5.	Shri Basanta Kumar Hens ADM, GMSD, Kolkata (Member)	 13/4/26
6.	Shri Tushar Kanti Hira Depot Supdt., GMSD, Kolkata (Member)	 13/4/26
7.	Shri Rajesh Kumar Sadhukhan Depot Supdt., GMSD, Kolkata (Member)	 13-4-26
8.	Shri Hemant Kumar Rai Pharmacist-c-Clerk, GMSD, Kolkata (Member)	 13/4/26
9.	Shri Tamoghna Acharya UDC, GMSD, Kolkata (Member)	 13/4/26

ATTENDANCE SHEET

The following representative/s of the firm/s attended the Pre-bid meeting held on 13.04.2026 at 11.00 Hours at Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata 700022 against Tender Number: 13(F-34)/PS/Tender/2025-26 (Tender ID No. 2026_DGHS_904967_1) for Supply of 101 Generic Drugs as per the Schedule of requirements.

Sl. No.	Name of the Firm and Address	Name of the Representative	Contact No./Mobile no.	E-mail id for communication	Signature
1	Bajaj Healthcare Ltd.	SUMAN GANGOPADHYAY	9674899869	suman@bajajhealth.com	
2	Quidmed	ISH CHADHA	9810482036	ishchadha23@gmail.com	
3	Zim LABORATORIES Ltd.	Manish mishra	911130376	manish.mishra@zimlab.in	
4	STADMED PVT LTD. KOLKATA	Katze Roy	9088464665 9088464665	katze@stadmed.co.in	
5	ALVENTA PHARMA LTD.	KARANDEEP SINGH.	9674460312	exports@alventapharma.com	
6	ALVENTA PHARMA LTD	VIKRANT AGARWAL	9830012693	..	
7	Evi's Laboratories Ltd. - Ahmedabad	Vicky shaw	7980347811	vicky.shaw@anushmed.com	
8					
9					
10					
11					